Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal paclitaxel
- Development stage
- Phase 4
- Lead developer
- Luye Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal paclitaxel is a formulation of paclitaxel, a chemotherapeutic agent used primarily in the treatment of various cancers. It works by stabilizing microtubules, preventing cell division, and thus inhibiting tumor growth. The liposomal formulation enhances the delivery and reduces side effects compared to traditional paclitaxel.
- Brand names
- LipusuNeoLipid paclitaxel
- Other names
- 紫杉醇脂质体
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on liposomal paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal paclitaxel.